Travere Therapeutics, Inc.
TVTX
$42.84
-$0.67-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 90.55% | 92.06% | 74.81% | -15.86% | -40.70% |
| Total Depreciation and Amortization | 57.40% | 39.46% | 33.56% | 21.75% | 11.22% |
| Total Amortization of Deferred Charges | -4.93% | -4.93% | 0.41% | 0.41% | 0.41% |
| Total Other Non-Cash Items | -78.68% | -85.32% | -67.19% | 124.45% | 152.66% |
| Change in Net Operating Assets | 57.71% | 77.79% | 6.41% | 53.37% | -1,040.93% |
| Cash from Operations | 124.66% | 115.91% | 78.47% | 60.04% | 49.46% |
| Capital Expenditure | -- | -- | -152.23% | -127.77% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -77.18% | -71.92% | -67.48% | -95.14% | -81.88% |
| Cash from Investing | -77.18% | -71.92% | -67.78% | -95.21% | -81.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -73.91% | -73.48% | 5,283.24% | 6,090.11% | 3,447.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | 10.98% | 19.82% | 27.03% |
| Cash from Financing | -122.96% | -124.00% | 18,394.85% | 57,158.50% | 11,570.59% |
| Foreign Exchange rate Adjustments | 2,437.50% | 350.93% | 35.73% | 206.01% | -108.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.70% | 9,510.03% | 169.11% | 211.09% | 115.78% |